Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis

Cancer

Volumn 109, Issue 8, 2007, Pages 1543-1549

  Fruehauf, Stefan ^a,b   Topaly, Julian ^a   Buss, Eike C ^a   Fischer, Thomas ^c   Ottmann, Oliver G ^d   Emmerich, Bertold ^e   Müller, Martin C ^f   Schuld, Peter ^g   Balleisen, Leopold ^h   Hehlmann, Rüdiger ^f   Ho, Anthony D ^a   Hochhaus, Andreas ^f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Center for Tumor Diagnostics and Therapy   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g NOVARTIS PHARMA GMBH   (Germany)

^h EVANGELISCHES KRANKENHAUS   (Germany)

Author keywords

Allogeneic transplantation; Chemotherapy; CML; Imatinib; Myeloid blast crisis

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; CYTARABINE; ETOPOSIDE; HYDROXYUREA; IMATINIB; INTERFERON; MITOXANTRONE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CYTARABINE; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MITOXANTRONE; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247131285     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22535     Document Type: Article

References (17)

1. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;9:3547-3553.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds.). World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
3. Derderian PM, Kantarjian HM, Talpaz M, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med. 1993;4:69-74.
4. Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;6:2632-2641.
5. Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1993;2:509-516.
6. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis; results of a phase II study. Blood. 2002;9:3530-3539.
7. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 2001;5:342-347.
8. Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol. 2002;19:3-14.
9. Fruehauf S, Topaly J, Buss EC, et al. Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia. Haematologica. 2002;7:ECR38.
10. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
11. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991;14:532-538.
12. Emig M, Saussele S, Wittor H, et al. Accurate and rapid' analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;3:1825-1832.
13. Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - inhibition of P-glycoprotein function by 17-AAG. Leukemia. 2005;9:1198-1206.
14. Radujkovic A, Topaly J, Fruehauf S, Zeller WJ. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. Anticancer Res. 2006;6:2169-2177.
15. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;54:2531-2541.
16. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;54:2542-2551.
17. Kimura S, Ashihara E, Maekawa T. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr Pharm Biotechnol. 2006;5:371-379.